Stay updated on Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial
Sign up to get notified when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.

Latest updates to the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page
- Check6 days agoChange DetectedA new revision entry labeled Revision: v3.5.5 with dates 2026-06-03 and 2026-06-02 was added to the page. The previous revision entry Revision: v3.5.4 with dates 2026-05-28 and 2026-05-27 appears to have been removed.SummaryDifference0.1%

- Check13 days agoChange DetectedAdded Nanjing Drum Tower Hospital in Nanjing, China and Johns Hopkins Myositis Center in Baltimore, MD as new study sites, increasing the total number of locations to 88.SummaryDifference0.5%

- Check20 days agoNo Change Detected
- Check28 days agoChange DetectedRevision updated from v3.5.3 to v3.5.4 on the page, indicating a new version of the document. This appears to be an administrative update with no visible changes to the study details or data presented.SummaryDifference0.0%

- Check49 days agoChange DetectedThe record page reflects a newer update timestamp/version and expands the listed study sites by adding additional participating hospitals in Japan and China, increasing the total number of locations from 80 to 86. Other displayed changes are version/date-related rather than changes to trial design or key clinical details.SummaryDifference0.6%

- Check56 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check85 days agoChange DetectedSite revision updated from v3.4.3 to v3.5.0. It seems to be an internal version update rather than a modification to visible page content.SummaryDifference0.0%

Stay in the know with updates to Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efgartigimod SubQ in Idiopathic Inflammatory Myopathy Clinical Trial page.